Answers are grounded in this paper and cite their sources.
Investigates the effectiveness of nal-IRI regimen after FOLFIRINOX in unresectable pancreatic cancer, suggesting a promising treatment approach.
Background and objective: Chemotherapy with 5-fluoruracil (5-FU)/folinic acid (FA), irinotecan (IRI) and oxaliplatin (OX) (FOLFIRINOX) is a standard first line treatment in advanced pancreatic cancer. Recently, an alternative regimen with nanoliposomal irinotecan (nal-IRI) (NALIRIFOX) has shown [for full text, please go to the a.m. URL]
No takes yet. Share an insight, caveat, or question.
Im et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: